- Redx Pharma said it would present a poster on Thursday at the American Society of Nephrology Kidney Week 2018 in San Diego.

The poster was related to the company's ROCK2 inhibitors for the treatment of chronic kidney disease.

Highly-selective ROCK2 inhibitors can provide a novel and effective therapy for patients with progressive kidney fibrosis who currently have few and largely ineffective therapy options, the company has claimed.

At 9:54am: [LON:REDX] Redx Pharma Plc share price was 0p at 7.5p

Story provided by